The cost of whole-genome and exome sequencing has gone down considerably, but when will these technologies become routine?
Whether they involve screening for active cells or introducing new receptors, therapies that boost the immune system’s response to cancer are becoming more specific and widely available.
Meet the top dogs of academia.
The rapid growth of genetic data and technologies might present additional liability risks to healthcare providers.
Novel gene expression tests could help clinicians make treatment decisions for heart disease patients.
A new graphic from research organization Decision Resources Group illustrates countries with biosimilars pathways, biosimilars in clinical trials, and regions with marketed biosimilars.
Tailor the adaptive immune response.
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved